By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Adamas Pharmaceuticals 

1900 Powell Street
Suite 1050
Emeryville  California  94608  U.S.A.
Phone: 510-450-3500 Fax: 510-428-0519




Company News
Adamas Pharmaceuticals (ADMS) Expands Its Phase 3 Program With ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Patients With Parkinson's Disease 10/29/2014 7:19:28 AM
Adamas Pharmaceuticals (ADMS) Reports Second Quarter 2014 Financial Results 8/8/2014 10:50:57 AM
United States Patent Issued To Adamas Pharmaceuticals (ADMS) 8/5/2014 3:49:07 PM
Adamas Pharmaceuticals (ADMS) To Present At JMP Securities Healthcare Conference 2014 6/17/2014 12:25:21 PM
Adamas Pharmaceuticals (ADMS) Announces Rater Training Data On ADS-5102 For Parkinson's Disease Patients With Levodopa-Induced Dyskinesia 6/10/2014 10:08:44 AM
Adamas Pharmaceuticals (ADMS) Initiates Phase 3 Trial For ADS-5102 In Parkinson's Disease Patients With Levodopa-Induced Dyskinesia 6/10/2014 9:03:15 AM
Adamas Pharmaceuticals (ADMS) Announces Data Update At The International Congress Of Parkinson's Disease And Movement Disorders 5/30/2014 6:40:08 AM
Emeryville's Adamas Pharmaceuticals (ADMS) Bags $25 Million Milestone Payment From Forest Laboratories, Inc. (FRX) 5/20/2014 5:20:00 PM
Adamas Pharmaceuticals (ADMS) Reports First Quarter 2014 Financial Results 5/14/2014 6:19:38 AM
Adamas Pharmaceuticals (ADMS) Provides Data Update On ADS-5102 At The American Academy of Neurology Annual Meeting 4/30/2014 7:34:34 AM